GenDx
Molecular diagnostics for personalized health care.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
* | $137m Valuation: $137m | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 36 % | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
GenDx is a science-based company specializing in molecular diagnostics for transplantation and personalized healthcare. The company focuses on providing advanced Human Leukocyte Antigen (HLA) typing solutions using Next-Generation Sequencing (NGS) technology. GenDx serves a global market of transplant centers, diagnostic laboratories, and research institutions. The business model revolves around the sale of proprietary software and reagents, such as NGSengine and SBTengine, which are essential for accurate HLA typing and compatibility testing. Revenue is generated through the sale of these products, along with continuous education and training programs that enhance the user experience and ensure optimal utilization of their solutions. GenDx also emphasizes excellent technical support and customer feedback to maintain high standards of service and product development.
Keywords: HLA typing, transplantation, molecular diagnostics, NGS technology, proprietary software, reagents, diagnostic laboratories, personalized healthcare, technical support, continuous education.
